Cohort study investigates secondary cancer incidence in metastatic cancers before and after ICI approval, suggesting important treatment implications.
This cohort study investigates incidence of secondary primary cancers before vs after approval of immune checkpoint inhibitors (ICIs) among patients with metastatic cancers.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: